Ablative radiation therapy for locally advanced pancreatic cancer: techniques and results

Standard doses of conventionally fractionated radiation have had minimal to no impact on the survival duration of patients with locally advanced unresectable pancreatic cancer (LAPC). The use of low-dose stereotactic body radiation (SBRT) in 3- to 5-fractionshas thus far produced a modest improvement in median survival with minimal toxicity and shorter duration of treatment, but failed to produce a meaningful difference at 2 years and beyond. A much higher biologically effective dose (BED) is likely needed to achieve tumor ablation The challenge is the delivery of ablative doses near the very sensitive gastrointestinal tract. Advanced organ motion management, image guidance, and adaptive planning techniques enable delivery of ablative doses of radiation (> = 100Gy BED) when more protracted hypofractionated regimens or advanced image guidance and adaptive planning are used. This approach has resulted in encouraging improvements in survival in several studies. This review will summarize the evolution of the radiation technique over time from conventional to ablative and describe the practical aspects of delivering ablative doses near the GI tract using cone beam CT image (CBCT) guidance and online adaptive MRI guidance.

[1]  B. Chauffert,et al.  Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of the 2000-01 FFCD/SFRO study. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

[2]  Albert C. Koong,et al.  Phase 2 Multi-institutional Trial Evaluating Gemcitabine and Stereotactic Body Radiotherapy for Patients With Locally Advanced Unresectable Pancreatic Adenocarcinoma , 2014, Cancer.

[3]  Pierre Michel,et al.  FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. , 2011, The New England journal of medicine.

[4]  T. Briere,et al.  Duodenal toxicity after fractionated chemoradiation for unresectable pancreatic cancer. , 2011, International journal of radiation oncology, biology, physics.

[5]  Hilde van der Togt,et al.  Publisher's Note , 2003, J. Netw. Comput. Appl..

[6]  David Goldstein,et al.  Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. , 2013, The New England journal of medicine.

[7]  W. Shi,et al.  Stereotactic body radiation vs. intensity-modulated radiation for unresectable pancreatic cancer , 2017, Acta oncologica.

[8]  Jeffrey E. Lee,et al.  Phase II trial of cetuximab, gemcitabine, and oxaliplatin followed by chemoradiation with cetuximab for locally advanced (T4) pancreatic adenocarcinoma: correlation of Smad4(Dpc4) immunostaining with pattern of disease progression. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  Jim Zhong,et al.  Outcomes for patients with locally advanced pancreatic adenocarcinoma treated with stereotactic body radiation therapy versus conventionally fractionated radiation , 2017, Cancer.

[10]  H. von der Maase,et al.  Phase-II study on stereotactic radiotherapy of locally advanced pancreatic carcinoma. , 2005, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[11]  David Goldstein,et al.  Effect of Chemoradiotherapy vs Chemotherapy on Survival in Patients With Locally Advanced Pancreatic Cancer Controlled After 4 Months of Gemcitabine With or Without Erlotinib: The LAP07 Randomized Clinical Trial. , 2016, JAMA.

[12]  T. Desser,et al.  Gemcitabine chemotherapy and single-fraction stereotactic body radiotherapy for locally advanced pancreatic cancer. , 2008, International journal of radiation oncology, biology, physics.

[13]  Parag J. Parikh,et al.  Poster ViewingHigh Dose Adaptive MRI Guided Radiation Therapy Improves Overall Survival of Inoperable Pancreatic Cancer , 2017 .

[14]  J P Cuijpers,et al.  Fast and robust online adaptive planning in stereotactic MR-guided adaptive radiation therapy (SMART) for pancreatic cancer. , 2017, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[15]  Gabriel O Sawakuchi,et al.  Focal Radiation Therapy Dose Escalation Improves Overall Survival in Locally Advanced Pancreatic Cancer Patients Receiving Induction Chemotherapy and Consolidative Chemoradiation. , 2016, International journal of radiation oncology, biology, physics.

[16]  Treatment of locally unresectable carcinoma of the pancreas: comparison of combined-modality therapy (chemotherapy plus radiotherapy) to chemotherapy alone. Gastrointestinal Tumor Study Group. , 1988, Journal of the National Cancer Institute.

[17]  T. Conroy,et al.  FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis. , 2016, The Lancet. Oncology.

[18]  Alison P. Klein,et al.  DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  David Cella,et al.  Gemcitabine alone versus gemcitabine plus radiotherapy in patients with locally advanced pancreatic cancer: an Eastern Cooperative Oncology Group trial. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  Sasa Mutic,et al.  Phase I trial of stereotactic MR-guided online adaptive radiation therapy (SMART) for the treatment of oligometastatic or unresectable primary malignancies of the abdomen. , 2017, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[21]  P. Engstrom,et al.  Treatment of locally unresectable cancer of the stomach and pancreas: a randomized comparison of 5-fluorouracil alone with radiation plus concurrent and maintenance 5-fluorouracil--an Eastern Cooperative Oncology Group study. , 1985, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.